Duan Fujiao, Yang Yang, Liu Weigang, Zhao Jie, Song Xiaoqin, Li Lifeng, Li Fuqin
Medical Research Office, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, Henan, China,
Department of Nosocomial Infection Management, First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Cancer Manag Res. 2018 Jul 17;10:2055-2069. doi: 10.2147/CMAR.S163415. eCollection 2018.
The aim of this study was to investigate the prognostic value of mircoRNA-17 and mircoRNA-17-5P (miR-17/17-5P) in patients with cancer.
We conducted a comprehensive search on published literature following the guidelines of the meta-analysis of observational studies in epidemiology group for design, implementation, and reporting. The methodological qualities for included studies were assessed using the quality in prognosis studies. The pooled hazard ratios (HRs) with 95% CIs for overall survival (OS) and progression-free survival/recurrence-free survival/disease-free survival (PFS/RFS/DFS) were calculated to appraise the associations between miR-17/17-5P expression and cancer prognosis.
A total of 21 studies involving 2099 subjects were analyzed in evidence synthesis. The results showed that high expression of miR-17 was associated with poor OS (HR=2.14; 95% CI: 1.69-2.71, <0.001) in patients with cancer, especially in Caucasian (HR=2.23; 95% CI: 1.58-3.14, <0.001) and digestive tract cancer (HR=1.29, 95% CI: 1.03-1.63, =0.03), and miR-17 expression was significantly correlated with PFS/RFS in cancer patients (HR=1.69, 95% CI: 1.29-2.22, <0.001). miR-17-5P overexpression was significantly linked with poor OS in cancer patients (HR=1.66; 95% CI: 1.31-2.09, =0.00), especially in Asian (HR=1.81; 95% CI: 1.37-2.40, <0.001), digestive tract cancer (HR=1.80; 95% CI: 1.29-2.50, <0.001), and serum sample (HR=1.76; 95% CI: 1.29-2.41, <0.001). miR-17-5P expression was significantly associated with DFS in cancer patients (HR=1.58, 95% CI: 1.07-2.35, =0.02).
High expression of miR-17 and miR-17-5P are significantly associated with poor survival in patients with cancer. This indicated that miR-17/17-5P may be a novel prognostic indicator in cancer.
本研究旨在探讨微小RNA - 17和微小RNA - 17 - 5P（miR - 17/17 - 5P）在癌症患者中的预后价值。
我们按照流行病学观察性研究的Meta分析指南，对已发表的文献进行了全面检索，涉及设计、实施和报告等方面。采用预后研究质量评估纳入研究的方法学质量。计算总生存（OS）以及无进展生存/无复发生存/无病生存（PFS/RFS/DFS）的合并风险比（HR）及95%置信区间（CI），以评估miR - 17/17 - 5P表达与癌症预后之间的关联。
在证据综合分析中，共纳入21项研究，涉及2099名受试者。结果显示，miR - 17高表达与癌症患者的不良OS相关（HR = 2.14；95% CI：1.69 - 2.71，<0.001），尤其是在白种人（HR = 2.23；95% CI：1.58 - 3.14，<0.001）和消化道癌症患者中（HR = 1.29，95% CI：1.03 - 1.63，=0.03），且miR - 17表达与癌症患者的PFS/RFS显著相关（HR = 1.69，95% CI：1.29 - 2.22，<0.001）。miR - 17 - 5P过表达与癌症患者的不良OS显著相关（HR = 1.66；95% CI：1.31 - 2.09，=0.00），尤其是在亚洲人（HR = 1.81；95% CI：1.37 - 2.40，<0.001）、消化道癌症患者（HR = 1.80；95% CI：1.29 - 2.50，<0.001）以及血清样本中（HR = 1.76；95% CI：1.29 - 2.41，<0.001）。miR - 17 - 5P表达与癌症患者的DFS显著相关（HR = 1.58，95% CI：1.07 - 2.35，=0.02）。
miR - 17和miR - 17 - 5P的高表达与癌症患者的不良生存显著相关。这表明miR - 17/17 - 5P可能是癌症的一种新型预后指标。
